Healthcare Data Security

RDGX is a utility token, not a currency or investment vehicle. Its primary function is to serve as a tool within the R-DEE protocol for healthcare professionals and industry-related users, providing practical and professional benefits such as cost offsets and access to premium features.

RDGX stands apart due to its dual consensus mechanism and its design for global healthcare use, a first in the industry. It is not just a cryptocurrency but a comprehensive tool that addresses specific healthcare operational needs. It is the only USA-based, fully certified by the DHHS (US Gov), complete health IT solution available in blockchain and crypto sphere (web3).

RDGX is used to facilitate transactions within the R-DEE suite, allowing for discounted access to services, enhanced security through HD-ID status, and the ability to engage in healthcare tokenization. It's a practical token with tangible applications in the healthcare sector.

Like any utility token, RDGX's market value may vary. However, its primary worth lies in its utility and the various applications it enables within the healthcare industry, rather than its investment potential.

RDGX is currently available through direct sale at www.radiologex.tech. There is a very limited Pre-Sale round, a Private sales round, and a forthcoming Public sales round.

RDGX is currently also available in limited quantities on a select group of exchanges, ensuring exclusive access to our tokens:

• LBANK
• COINSBIT
• AZBIT
• TOKPIE

Furthermore, we are in the final stages of securing a listing on an additional exchange that ranks within the top 10 by market volume, which will further enhance the accessibility of RDGX to our users.

Absolutely, our Direct Sales are unfolding in three key stages:

Exclusive Pre-Sale Stage: Offering 2.5M RDGX Tokens at $1.00 each, with a generous 100% bonus* on all purchases. Only 2.5M RDGX Tokens are available in this round. A minimum purchase is required.

Private Sales Round: February 1 to May 31, 2024, or until sold out. RDGX Tokens are priced at $1.00 each, featuring tiered bonuses ranging from 15% to 35%, with a minimum purchase of 1000 tokens. A total of 10M RDGX Tokens are available for this round.

Public Sales Round: June 1 to August 31, 2024, or until sold out. Tokens are available at $2.00 each. This round offers 20M tokens, with no minimum purchase required. Unlock exclusive bonuses of 5%, 10%, or 15% on every purchase.

Each stage is designed with unique incentives, providing limited token availability to ensure exclusivity for early adopters.

*Note: Bonuses are effectively applied as discounts at the point of purchase. Thus, a 100% token bonus equates to a 50% discount on the listed token price at checkout."

Certainly. Our vesting schedules are designed with the ecosystem’s longevity in mind:

Pre-Sale and Private Buyers: A one-year lock-up to support ecosystem stability.

Public Buyers: Immediate market access post-purchase, no lock-up.

Team and Affiliates: A phased three-year vesting, with incremental releases at 10%, 20%, and 70% over each subsequent year.

Philanthropy Initiatives: Managed by the Radiologex Foundation, these allocations are vested across a decade, promoting long-term benefits.

Additionally, under our Fair Launch, we're introducing a limited Free Nodes Initiative, vesting over three years to broaden technology access and adoption.

Node Validator Rewards start accruing from January 2024, with immediate collateral leverage for node operation and no delays in reward accrual.

Listing RDGX on exchanges first was a calculated move to establish its market presence and value. It enabled early price discovery and market validation, ensuring liquidity and wider accessibility. This step also signaled trust and compliance, laying the groundwork for stable pricing and strategic partnerships. Our investment in these listings reflects our commitment to RDGX's long-term potential and a stable foundation for its role in healthcare technology.

Our focus with RDGX is on its utility in the R-DEE ecosystem, vital for enhancing healthcare technology. While RDGX is not designed as an investment vehicle and we avoid speculation on its valuation, its value is inherently linked to its utility and adoption within the healthcare sector.

With RDGX aimed at a broad market including 75 million healthcare professionals and a billion patients, its practical use and adoption are key factors that naturally shape its value. We encourage observing the evolution of blockchain technology in healthcare to understand RDGX's potential impact and organic growth in the sector.

RDGX's rapid rise to a $400 million market cap within just 60 days reflects its strong utility and market acceptance, especially in the healthcare sector, rather than being a deterrent. This market valuation indicates robust demand and adoption.

Consider also the estimated 70% of RDGX's circulating supply earmarked for Node Validator collateral, creating a scarcity in the market. This should be viewed in light of RDGX's utility and its ecosystem role.

The anticipated scarcity, coupled with RDGX's utility, suggests potential for continued growth and adoption, reinforcing its value as a practical tool in healthcare technology.

Currently, direct sales of RDGX tokens are restricted in several countries and regions due to legal and regulatory frameworks. These include Cuba, the USA, North Korea, Iran, Libya, mainland China (excluding Hong Kong, Macau, and Taiwan), South Sudan, North Sudan, Syria, Crimea, and any jurisdictions under US, UN, or other relevant sanctions.

We recommend that potential buyers check the legal requirements in their respective jurisdictions before participating in the sale.

RDGX is committed to robust market presence and vitality. To this end, we've engaged with two globally acclaimed, award-winning marketing firms to spearhead our international marketing campaigns. Alongside these strategic initiatives, we deploy expert market-making tactics to enhance price stability and ensure ongoing liquidity, providing a solid foundation for RDGX in the secondary market.

The availability of our Node Validator, known as R-MIN, is intentionally capped at 12,500 licenses. This is in addition to the 2,500 nodes already established by the company to ensure optimal network operations, bringing the total to a maximum of 15,000 nodes. We encourage interested parties to act swiftly to secure their node eligibility, as once these licenses are allocated, there will be no further issuance.

Node licenses are free, but Node Validators must complete KYC via the R-DEE app. While the license is complimentary, operators need to independently procure a Virtual Private Server (VPS) for each node. The typical cost for a VPS is about $5.00 per month, per node, payable to your chosen VPS provider, not Radiologex. As essential partners in our network, Node Validators play a key role and receive compensation for their contribution to our enterprise-grade blockchain network.

To become a Node Validator, hold 10,000 RDGX tokens as collateral and complete KYC via the R-DEE app. Once approved for a Node Validator license, you can choose to run a node externally or use the automated R-DEE Settle Module for easy operation. Remember, your collateral is under your control, but stopping node operation or withdrawing collateral pauses reward accrual for 30 days. Full terms and details for Node Validators will be provided soon.

Beyond the initial ten-year reward phase, Node Validator compensation transitions from the reward pool to a sustainable fee-based model linked to the R-DEE platform's network fees. This ensures ongoing income for Node Validators, reflecting the critical role they play. Continual income is assured for active license holders who meet collateral and credit score requirements, reinforcing our commitment to a lasting and mutually beneficial partnership with our Node Validators.

RDGX transactions are free of any extra network fees imposed by the R-DEE Protocol. As an ERC20 token, the only fees incurred are the standard Ethereum network gas fees. This approach ensures a straightforward and cost-effective transaction experience for RDGX users.

RDGX deeply values community engagement and we actively facilitate this through various social and communication channels. Nevertheless, community voting is not implemented within the RDGX framework. The core reason lies in the proprietary nature of the RDXG network, which is tailored to serve the high-stakes realm of global healthcare IT. Given the critical need for unparalleled security and compliance in handling sensitive healthcare data and services, RDGX operates as a private chain. This structure is intentional, ensuring that enterprise-level decisions maintain the strictest standards of privacy and reliability required by our users.

The pricing of RDGX at $1.00 for the private round and $2.00 for the public round is based on its significant role in the R-DEE ecosystem and the extensive healthcare IT sector it supports. This valuation mirrors the token’s potential to enhance healthcare operations through R-DEE's nine specialized modules.

Moreover, RDGX's pre-blockchain valuation of $370 million by Mathys & Squire, based on its product and intellectual property, underscores its inherent value. Given its modest circulating supply due to allocation for Node Validator collateral, RDGX's market valuation is positioned reasonably, especially considering its ready-to-market status and actual utility, as opposed to speculative potential.

RDGX's pricing reflects both its current utility in healthcare IT and its capacity for future growth and integration within the industry.